← Leaderboards
Joseph Paul Eder
Beth Israel Deaconess Medical Center
$256,083
Attributed
$256,083
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$256,083 · 3
By mechanism
M01$256,083 · 3
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Michael B Atkins$4,622,469
- David McDermott$9,360,637
- Bruce J Dezube$965,277
- Steven C. Schachter$10,007,385
- Harold Fisher Dvorak$13,877,917
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationHuman Therapy EvaluationClinical ResearchClinical Trial Phase IPharmacokineticsAntineoplasticsIntravenous AdministrationRecombinant ProteinsAngiogenesis InhibitorsNeoplasm /CancerDosagePatient Oriented ResearchDrug Adverse EffectAntineoplastic AntibioticsInjection /Infusion
Grant awards (9)
PHASE I KRN5500 AS A 72 HOUR CONTINUOUS IV INFUSION IN PTS WITH SOLID TUMORS$55,974
M01 · FY2005 · RR
KRN5500 GIVEN AS A 72HR CONTINUOUS IV INFUSION EVERY 21 DAYS PTS W/SOLID TUMORS$26,776
M01 · FY2005 · RR
Phase I KRN5500 as a 72 Hour Continuous IV Infusion in Pts with Solid Tumors$167,249
M01 · FY2004 · RR
KRN5500 GIVEN AS A 72HR CONTINUOUS IV INFUSION EVERY 21 DAYS PTS W/SOLID TUMORS$6,084
M01 · FY2004 · RR
INTRAVENOUS RECOMBINANT HUMAN ENDOSTATIN IN CANCER$0
M01 · FY2002 · RR
INTRAVENOUS RECOMBINANT HUMAN ENDOSTATIN IN CANCER$0
M01 · FY2001 · RR
INTRAVENOUS RECOMBINANT HUMAN ENDOSTATIN IN CANCER$0
M01 · FY2000 · RR
INTRAVENOUS RECOMBINANT HUMAN ENDOSTATIN IN CANCER$0
M01 · FY2000 · RR
INTRAVENOUS RECOMBINANT HUMAN ENDOSTATIN IN CANCER$0
M01 · FY2000 · RR